GH Research GHRS Stock
GH Research Price Chart
GH Research GHRS Financial and Trading Overview
| GH Research stock price | 9.53 USD |
| Previous Close | 11.62 USD |
| Open | 11.75 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 800 |
| Day's Range | 11.44 - 12.22 USD |
| 52 Week Range | 5.7 - 17.41 USD |
| Volume | 20.34K USD |
| Avg. Volume | 75.94K USD |
| Market Cap | 626.85M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.75 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.4 USD |
GHRS Valuation Measures
| Enterprise Value | 465.16M USD |
| Trailing P/E | N/A |
| Forward P/E | -9.48819 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.5919552 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -14.073 |
Trading Information
GH Research Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 14.21% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 17.41 USD |
| 52 Week Low | 5.7 USD |
| 50-Day Moving Average | 9.95 USD |
| 200-Day Moving Average | 10.32 USD |
GHRS Share Statistics
| Avg. Volume (3 month) | 75.94K USD |
| Avg. Daily Volume (10-Days) | 25.57K USD |
| Shares Outstanding | 52.02M |
| Float | 12.42M |
| Short Ratio | 21.97 |
| % Held by Insiders | 40.39% |
| % Held by Institutions | 61.38% |
| Shares Short | 1.25M |
| Short % of Float | 5.78% |
| Short % of Shares Outstanding | 2.39% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -7.92% |
| Return on Equity (ttm) | -10.80% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -33053000 USD |
| Net Income Avi to Common (ttm) | -27630000 USD |
| Diluted EPS (ttm) | -0.53 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 162.82M USD |
| Total Cash Per Share (mrq) | 3.13 USD |
| Total Debt (mrq) | 1.13M USD |
| Total Debt/Equity (mrq) | 0.47 USD |
| Current Ratio (mrq) | 24.814 |
| Book Value Per Share (mrq) | 4.649 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -27083000 USD |
| Levered Free Cash Flow (ttm) | -15899500 USD |
Profile of GH Research
| Country | United States |
| State | N/A |
| City | Dublin |
| Address | Joshua Dawson House |
| ZIP | D02 RY95 |
| Phone | 353 1 437 8334 |
| Website | https://www.ghres.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 32 |
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Q&A For GH Research Stock
What is a current GHRS stock price?
GH Research GHRS stock price today per share is 9.53 USD.
How to purchase GH Research stock?
You can buy GHRS shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GH Research?
The stock symbol or ticker of GH Research is GHRS.
Which industry does the GH Research company belong to?
The GH Research industry is Biotechnology.
How many shares does GH Research have in circulation?
The max supply of GH Research shares is 62.03M.
What is GH Research Price to Earnings Ratio (PE Ratio)?
GH Research PE Ratio is now.
What was GH Research earnings per share over the trailing 12 months (TTM)?
GH Research EPS is -0.75 USD over the trailing 12 months.
Which sector does the GH Research company belong to?
The GH Research sector is Healthcare.
GH Research GHRS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}